Dr. Gandara Discusses PD-L1 as a Biomarker in Lung Cancer

David R. Gandara, MD
Published: Thursday, Sep 07, 2017



David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, treasurer, International Association for the Study of Lung Cancer (IASLC), discusses PD-L1 as a biomarker in lung cancer.

PD-L1 has had ups and downs as a biomarker, says Gandara. It seemed promising early on, but after data with nivolumab (Opdivo) came out in non-small cell lung cancer, it was no longer seen as a specific indicator.

Gandara adds that the field is still grasping for the best biomarkers to use in this disease.
 


David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, treasurer, International Association for the Study of Lung Cancer (IASLC), discusses PD-L1 as a biomarker in lung cancer.

PD-L1 has had ups and downs as a biomarker, says Gandara. It seemed promising early on, but after data with nivolumab (Opdivo) came out in non-small cell lung cancer, it was no longer seen as a specific indicator.

Gandara adds that the field is still grasping for the best biomarkers to use in this disease.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Community Practice Connections™: 4th Annual Miami Lung Cancer Conference®Jun 30, 20187.0
Publication Bottom Border
Border Publication
x